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Introduction
Unlike other common neurodegenerative conditions like Alz-
heimer’s disease (AD) and Parkinson’s disease (PD), which are 
characterized by protein misfolding and aggregation, the cause of 
Huntington’s disease (HD) is known with certainty: a CAG-repeat 
expansion in the HTT gene encoding huntingtin (HTT) protein (1). 
Mutant huntingtin (mHTT) contains an expanded polyglutamine 
tract and causes neuronal dysfunction and death, producing the 
progressive and ultimately fatal combination of behavioral, cog-
nitive, and motor symptoms that characterize HD (2, 3). There 
is currently no treatment that alters the progression of HD, but 
numerous approaches are now entering the clinic, including strat-
egies to decrease production or enhance clearance of mHTT (4).
Because of its complete penetrance, a genetic test can reli-
ably identify those individuals destined to develop HD. However, 
despite an association between the length of the CAG repeat 
and age at onset, the clinical course of HD can be variable and 
unpredictable and is partly determined by unknown genetic and 
environmental factors (5). Some of these likely relate to structural 
or functional properties of mHTT or its cleaved and posttransla-
tionally modified species (3). mHTT has been extensively studied 
in model systems, but in humans its study is limited to indirect 
methods such as measurement of brain atrophy or the examina-
tion of postmortem tissue.
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found good mHTT signal recovery rates (91%–114%) across the 
whole quantifiable range of the assay. This indicates the capac-
ity of the assay to quantify precisely known amounts of reference 
analyte in real samples and that the experimental conditions con-
trol satisfactorily for any potential CSF matrix effects (generally 
caused by heterophilic antibodies, proteolytic activity, or nonspe-
cific antibody binding; Supplemental Figure 1, C and D).
mHTT is detected in mutation carrier, but not control partici-
pant, CSF. Next, we used the assay to quantify mHTT in CSF and 
plasma from 2 independent cohorts (London, n = 12 and Vancou-
ver, n = 40; Table 1). The Vancouver cohort spanned a wider range 
of participants than did the London cohort, including those with 
advanced disease. There were no significant differences in age, 
sex, or CAG repeat length between the cohorts.
We were able to detect mHTT protein in the CSF samples: 
mHTT was present in the CSF of almost all HTT mutation carri-
ers, but not in that of control volunteers (Figure 2). In the London 
cohort, we were able to detect mHTT in the CSF of all 9 mutation 
carriers (mean ± SD 182.5 ± 106.3 fM; P = 0.00455), but not in the 
CSF of any of the 3 controls (Figure 2A). The odds ratio (OR) for the 
presence of mHTT in mutation carriers versus controls was incalcu-
lably high, with a lower 95% confidence bound of 33.1. In the Van-
couver cohort, we detected CSF mHTT in 26 of 28 HTT mutation 
carriers (289.1 ± 194.6 fM, P = 7.79 × 10–8; Figure 2B), but not in any 
of the 10 controls; the OR for detecting mHTT in mutation carriers 
was again incalculably high (lower 95% confidence bound of 14.8).
There was no statistically significant effect of age or sex on 
CSF mHTT concentrations in either cohort. mHTT concentrations 
were somewhat higher in the Vancouver cohort (216.9 ± 33.3 fM) 
than in the London cohort (136.8 ± 35.4 fM), but this was not statis-
tically significant (P = 0.217). The Vancouver cohort contained 
subjects with more advanced disease than did the London cohort. 
There was no significant difference in mean CSF hemoglobin con-
centrations between the London and Vancouver cohorts (P = 0.63), 
suggesting no major differences in CSF quality.
CSF mHTT concentration is higher in manifest than in premani-
fest HD participants. CSF mHTT concentrations were significantly 
higher in participants with manifest HD (239.2 ± 166.8 fM) than in 
premanifest mutation carriers (69.0 ± 4.6 fM) in the London cohort 
(P = 0.0035; Figure 2A). This was reproduced in the Vancouver 
cohort, in which the mean HTT concentration was 365.0 ± 177.6 
fM in manifest HD participants compared with 137.4 ± 130.4 fM in 
premanifest HD participants (P = 0.0006; Figure 2B).
Quantification of disease-associated proteins in human cere-
brospinal fluid (CSF) is increasingly valuable for diagnosis, mon-
itoring disease progression, and assessing treatment response in 
neurodegenerative diseases including AD, PD, and amyotrophic 
lateral sclerosis (ALS) (6–9). Despite its ubiquitous expression, 
mHTT has never been detected in human CSF, most likely due 
to its predominantly intracellular localization, resulting in very 
low concentrations in the CSF. Nevertheless, since mHTT is the 
known cause of HD neuropathology, its study in an accessible 
CNS compartment, such as CSF, will be highly informative. The 
ability to quantify mHTT in CSF would have immediate poten-
tial as a pharmacodynamic biomarker in therapeutic trials of 
HTT-lowering treatments, and, if independently capable of pre-
dicting phenotypic features, CSF mHTT could serve as a useful 
biomarker of HD progression.
We previously described an assay that quantifies soluble 
mHTT in peripheral blood leukocytes and showed that mHTT 
concentration levels were associated with disease progression and 
brain atrophy rates, but this assay was insufficiently sensitive to 
detect the protein in patient plasma or CSF (10). Here, we report 
what we believe to be a novel femtomolar-sensitive, single-mole-
cule counting (SMC) immunoassay for soluble mHTT and its use 
to quantify mHTT in CSF from 2 cohorts of control volunteers and 
HD mutation carriers.
Results
SMC immunoassay quantifies mHTT sensitively, specifically, and 
reproducibly. First, we used the SMC immunoassay to detect puri-
fied recombinant human HTT N548 proteins with polyglutamine 
lengths in the mutant (46Q) and WT (19Q) ranges. We found 
marked selectivity for mutant HTT over WT HTT (Figure 1, A 
and B). This specificity is conferred by the MW1 anti-HTT polyQ 
antibody, as previously demonstrated in other assay platforms (11, 
12). The 2B7 antibody, meanwhile, binds the N-terminal 17 amino 
acids of mutant and WT HTT (13). A low femtomolar detection 
threshold and broad dynamic range were shown with recombi-
nant N548 46Q mHTT (Figure 1C). High selectivity of the assay 
for HTT over other proteins was demonstrated by an approximate 
80% drop in signal after immunodepletion by the anti-HTT anti-
body 4C9 (Supplemental Figure 1B; supplemental material avail-
able online with this article; doi:10.1172/JCI80743DS1).
Using artificial and human CSF from control participants and 
HD mutation carriers spiked with recombinant HTT proteins, we 
Figure 1. The mHTT SMC immunoassay is spe-
cific and sensitive. (A) Schematic of mHTT (not 
to scale) indicating the epitopes bound by the 
2B7 and MW1 antibodies used for the assay. 2B7 
binds residues 1–17 of the N terminus (11), while 
MW1 conveys specificity for the mutant protein 
by binding preferentially to the expanded 
polyglutamine tract (13). (B) Detection of puri-
fied recombinant HTT proteins with the SMC 
immunoassay shows specificity for mutant 
(mHTT) over WT human HTT protein. (C) Deter-
mination of the assay’s LLoQ and ULoQ shows 
a low femtomolar detection threshold and 
broad dynamic range.
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centration and the Unified Huntington’s Disease Rating Scale   
(UHDRS) motor score (R = 0.629, P < 0.0001; Figure 3D). This 
association remained significant after controlling for disease bur-
den score (R = 0.516, P = 0.0167).
Notably, significant negative associations were also found 
between CSF mHTT concentration and performance on 4 of 
4 cognitive tasks assessed in the Vancouver participants: sym-
bol-digit modality test (R = –0.565, P = 0.0062); Stroop color 
matching (R = –0.620, P = 0.0012); Stroop word matching   
(R = –0.612, P = 0.0015); and Stroop interference (R = –0.505,   
P = 0.012; Supplemental Table 1). All but the Stroop interference 
score remained statistically significant after controlling for dis-
ease burden score. FDR values (q values), calculated to account 
for multiple comparisons, were less than 0.05 for all the raw asso-
ciations between mHTT and cognitive scores, as well as for the 
disease burden–controlled associations of mHTT with Stroop 
color and word matching.
These findings indicate that CSF mHTT concentration has 
independent predictive value for these clinical features of HD, 
beyond the known predictive ability of age and CAG repeat length.
CSF mHTT concentrations are associated with those of neuronal 
markers. To explore the origin and significance of the mHTT 
detected in CSF, we examined the CSF concentrations of the neu-
ronal proteins tau and neurofilament light chain (NFL) in the same 
CSF mHTT concentration is higher at later disease stages. To 
evaluate whether mHTT levels change over the course of HD, 
we examined its association with pathological disease burden 
score, a function of age and CAG repeat length that predicts many 
features of HD onset and progression (14, 15). CSF mHTT con-
centrations were significantly positively associated with the dis-
ease burden score among HTT mutation carriers in the London 
cohort (R = 0.909, P = 0.0007; Figure 3A). This was replicated in 
the Vancouver cohort, albeit with a lower correlation coefficient   
(R = 0.695, P = 0.0001; Figure 3B).
To investigate whether the level of mHTT increases as disease 
onset approaches in premanifest mutation carriers, we examined 
its association with 5-year conditional onset probability — an age- 
and CAG-based estimation of a premanifest individual’s proximity 
to clinical onset (16) — and found a significant positive association 
(R = 0.661, P = 0.0139; Figure 3C). Notably, the 2 HD participants 
with CSF mHTT levels below the limit of detection were among 
those premanifest mutation carriers furthest from the predicted 
onset (5-year onset probability of 0.003 and 0.04).
CSF mHTT concentration independently predicts clinical fea-
tures of HD. Next, we examined whether CSF mHTT levels have 
the ability to predict clinical parameters in HD, beyond the known 
predictive power of CAG repeat length and age. We found a statis-
tically significant positive association between CSF mHTT con-
Table 1. Demographic and clinical characteristics of participants in the London and Vancouver cohorts
Cohort Group n Age Male/female CAG repeat length Disease burden score TFC
London (total n = 12) Control 3 45.5 (17.1) 2:1
Premanifest 3 39.7 (9.7) 1:2 42.0 (1.0) 252.3 (24.2) 13.0 (0)
Early 3 42.8 (3.8) 1:2 45.0 (1.0) 405.9 (44.3) 12.3 (0.6)
Moderate 3 58.1 (1.9) 2:1 43.0 (1.0) 434.3 (43.7) 5.0 (1.0)
Vancouver (total n = 40) Control 10 47.2 (16.3) 4:6
Premanifest 10 39.4 (13.7) 5:5 42.5 (2.9) 255.8 (115.5) 12.5 (0.7)
Early 7 48.7 (6.8) 2:5 43.9 (3.0) 392.9 (103.8) 10.0 (1.5)
Moderate 2 64.0 (11.3) 2:0 39.0 (2.8) 240.0 (220.6) 5.0 (0.0)
Advanced 11 54.5 (11.7) 6:5 46.1 (6.2) 533.4 (179.2) 1.4 (1.4)
TFC, total functional capacity on the UHDRS. Values represent the mean (SD).
Figure 2. mHTT is detectable in CSF from HTT mutation 
carriers but not from control participants in 2 popula-
tions. (A) London population (n = 12) and (B) Vancouver 
population (n = 30). CSF mHTT concentration was signifi-
cantly elevated in manifest HD subjects compared with 
that in premanifest HD subjects in both populations. 
Horizontal bars indicate the group means. Data were 
calculated by weighted-least-squares ANOVA.
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Discussion
We report here, for the first time to our knowl-
edge, the first successful quantification of 
mHTT in human CSF, obtained from 2 inde-
pendent cohorts; mHTT was not detected in 
control volunteer CSF, but was reliably quan-
tifiable at femtomolar sensitivity in CSF from 
almost all mutation carriers. Moreover, we 
report what we believe to be the first direct 
evidence that higher mHTT load is associ-
ated with lower cognitive function and more 
severe motor dysfunction in patients. That 
these clinical associations remain present 
after controlling for disease burden score sug-
gests that CSF mHTT may have substantial 
additional independent value as a biomarker 
for HD. To our knowledge, this is the first time 
a biochemical marker has shown the ability to independently pre-
dict such phenotypic features of HD.
Further, mHTT concentration in CSF has other associations of 
potential clinical relevance: it is significantly associated with onset 
probability in premanifest HD and disease burden score in all 
mutation carriers, and the mean mHTT concentration is approx-
imately 3-fold higher in manifest than in premanifest HD. Given 
that mHTT causes HD, its quantification in CSF could potentially 
be a molecular biomarker of disease progression, with possible 
value for the design and conduct of clinical trials, and a window 
into the natural history of the disease.
CSF mHTT levels were not associated with age, sex, CSF 
hemoglobin or total protein concentration, or plasma mHTT con-
centration, implying that our findings are not artifacts of demo-
graphics, blood contamination, or transfer of mHTT from periph-
eral blood into the CSF. That CSF mHTT was not associated with 
total protein concentration suggests that a general protein increase 
in HD does not explain our CSF mHTT findings.
The CSF mHTT concentrations seen in the Vancouver cohort 
were somewhat higher than in the London cohort, but this differ-
ence was not statistically significant. The Vancouver cohort con-
tained subjects with advanced disease (who also had higher mHTT 
concentrations), as well as more premanifest subjects closer to 
predicted disease onset. Furthermore, in contrast to the London 
samples, the Vancouver CSF samples were also not standardized 
for diet or time of day. The possible effects of diet, time of day, sam-
ple handling, and other factors on CSF mHTT concentration are 
currently under investigation and may be minimized in the future 
by standardization of collection and processing procedures.
samples. We found a significant positive linear association between 
CSF mHTT concentration and CSF tau concentration (R = 0.791,   
P = 0.0111; Figure 4A) in the London cohort. This was reproduced 
in the Vancouver cohort (R = 0.577, P = 0.0008; Figure 4B).
A significant association between the CSF concentrations of 
mHTT and NFL was also seen in the London cohort (R = 0.886,   
P = 0.0015; Figure 4C); this was replicated with high significance 
in the Vancouver cohort (R = 0.919, P < 0.0001; Figure 4D).
Unlike mHTT concentration, tau and NFL concentrations 
were not significantly associated with cognitive scores after con-
trolling for disease burden (Supplemental Table 1), with the sol-
itary exception of NFL and Stroop color matching (R = –0.626,   
P = 0.022), an association that did not survive FDR correction. 
We note, however, that other NFL cognition correlation estimates 
were of a magnitude similar to that of the mHTT correlations, 
though the available sample of NFL measures was smaller.
There was no significant positive or negative association 
between the CSF concentrations of mHTT and hemoglobin in 
either cohort (P = 0.125 for London; P = 0.945 for Vancouver; 
Supplemental Figure 2A), nor between those of mHTT and 
total protein (P = 0.835 for London; P = 0.844 for Vancouver; 
Supplemental Figure 2B).
mHTT was detected in plasma from all mutation carriers 
(Supplemental Figure 2C). However, there was no significant 
association between CSF and paired plasma mHTT concentra-
tions in the entire dataset (r = 0.454, 95% bootstrap CI –0.145 
to 0.740, P ≈ 0.14) or after the removal of 2 participants with 
extreme values for both measures (r = –0.074, P = 0.670; Sup-
plemental Figure 2D).
Figure 3. CSF mHTT concentration correlates sig-
nificantly with disease stage. mHTT concentration 
was positively associated with the disease burden 
score in both (A) London (n = 9) and (B) Vancouver 
(n = 30) cohorts. Significant positive associations 
were also seen with (C) 5-year conditional onset 
probability in premanifest participants (n = 13) 
and (D) in UHDRS motor scores (n = 39). Data were 
calculated by linear regression analysis.
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(Figure 1A), which contains the polyglu-
tamine expansion thought to be central to 
the neurodegeneration of HD (19, 20). Our 
SMC immunoassay will therefore detect 
any soluble mHTT species containing the 
2B7 and MW1 epitopes, namely residues 
1–17 and the polyglutamine repeat. Thus, it 
will detect full-length mHTT protein, exon 
1 fragments, as well as other fragments of 
mHTT that contain the N terminus, but it 
will not detect any species that lacks the N 
terminus or an expanded polyglutamine 
tract. We cannot exclude the possibility of 
a contribution from other mHTT species 
such as mHTT oligomers or aggregates. 
Nonetheless, our assay represents the 
first opportunity to study mHTT protein 
biology in vivo in the patient’s CNS and 
will empower future studies to character-
ize mHTT species in CSF and their role in HD pathobiology. We 
are developing complementary CSF assays for total HTT and its 
cleaved fragments to understand which HTT species are associ-
ated with neurodegeneration or neuroprotection.
We observed that the CSF mHTT concentration increases 
with disease progression. We previously reported a similar phe-
nomenon in peripheral leukocytes and demonstrated the pres-
ence of N-terminal mHTT fragments in these cells, suggesting 
that progressive accumulation of N-terminal mHTT fragments 
could underlie the increase (10). N-terminal fragments are known 
to accumulate in neurons as part of the neuropathology in ani-
mal models (21), and it could be that this accumulation leads to 
increased cell death, elevating mHTT concentration in the CSF as 
the disease progresses. The linear associations with tau and NFL 
concentrations suggest that mHTT may be an indicator of overall 
dysfunction and/or death of mHTT-containing cells.
The specificity of our assay for mutant over WT HTT protein 
comes from the polyglutamine-binding MW1 antibody epitope. 
By definition, this introduces some tendency for longer polyglu-
tamine tracts to generate a higher signal. However, we previously 
demonstrated the use of an allelic series of purified mHTT pro-
teins (10) and show again here (Figure 1) that mHTT concentra-
tion, rather than polyglutamine length, is the overwhelming con-
tributor to the binding of this antibody in the polyglutamine range 
seen in 93% of patients (16).
Somatic mosaicism for the HTT CAG repeat length has been 
observed in human postmortem brain, though it is not clear 
Several findings point to the CNS as the origin of the mHTT 
protein detected by this assay in the CSF of participants. We 
found very strong linear correlations between the concentration 
of CSF mHTT and the concentrations of tau and NFL, both of 
which are expressed almost exclusively in neurons and are asso-
ciated with various forms of neurodegeneration (6, 8, 9).
Our SMC immunoassay uses an optimized antibody combina-
tion with high specificity for polyglutamine-expanded HTT, allied 
with a platform that enhances the signal-to-noise ratio through 
incubation with antibody-coated paramagnetic microparticles, 
followed by laser interrogation in a capillary flow cell to detect 
individual analyte molecules. SMC immunoassays have high sen-
sitivity and dynamic ranges that are orders of magnitude above 
those of conventional immunoassays (17).
As emphasized above, the association between CSF mHTT 
concentration and motor and cognitive scores survived statistical 
correction for disease burden score. The same did not hold true 
for tau protein, which implies the specificity of mHTT among CSF 
protein markers of neuropathology as a biomarker with an inde-
pendent capacity to predict clinically relevant features of the dis-
ease. This, of course, is in keeping with the known etiological role 
of the protein. Our NFL findings in a relatively small sample subset 
identify this protein as a potential HD biomarker, and we continue 
to investigate this possibility (18).
The mechanism underlying the increasing mHTT concen-
trations warrants further study. Crucially, the 2B7 and MW1 
antibodies bind distinct domains of the N terminus of mHTT 
Figure 4. CSF concentrations of mHTT and of the 
neuronal proteins tau and NFL are significantly 
associated. Significant positive linear associ-
ations were seen between CSF concentrations 
of mHTT and tau in (A) London (n = 9) and (B) 
Vancouver (n = 30) cohorts. A strikingly close 
association was seen between CSF mHTT concen-
tration and NFL concentration in the (C) London 
(n = 9) and (D) Vancouver (n = 20) cohorts. Data 
were calculated by linear regression analysis.
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whether such expansion is a driver of region-selective neuronal 
death, or indeed when it arises during the course of the disease 
(22–24). One might hypothesize that an increasing polyglutamine 
count may contribute to the increasing mHTT signal with progress-
ing disease. However, the above-noted primary dependence of the 
assay on mHTT concentration rather than on polyglutamine count 
suggests that a rising mHTT concentration is likely the main driver 
of the increasing signal observed. Nonetheless, the possibility of a 
contribution from somatic instability warrants further study.
The present work demonstrates the relationship between CSF 
mHTT and disease progression, as evaluated by cross-sectional 
examination of participants across the disease spectrum. To 
establish whether CSF mHTT is a useful biomarker of HD onset 
and progression, the crucial next step will be to exploit this assay 
to study CSF mHTT and its relationship to clinical progression 
longitudinally in patients.
In other neurodegenerative conditions, CSF quantification of 
disease-associated CNS proteins now has direct clinical utility in 
guiding clinical decision making around diagnosis. SMC assays 
have also been used to detect low-abundance protein species of 
interest in AD (25–27). While a genetic test can predict who will 
develop HD, the diagnosis of motor onset is currently a clinical 
one. Once better understood, CSF mHTT levels may come to 
have a role, alongside other biomarkers, in supporting clinical 
decision making in HD, especially if disease-modifying therapeu-
tic agents become available.
Finally, therapeutic approaches for HD that aim to lower 
mHTT protein production at the DNA/RNA level or enhance 
mHTT clearance from cells are now being tested in clinical trials 
(4). The ability to quantify soluble mHTT directly in an accessible 
CNS tissue will very likely be of considerable value as a pharma-
codynamic biomarker in such trials. The assay we describe here 
has the potential to support the clinical development of these and 
other therapeutic agents for HD.
Methods
Participant recruitment.  HTT mutation carriers were identified by 
genetic testing and clinical stage determined using the UHDRS, as 
previously described (28).
Sample collection and processing. A dedicated CSF collection from 
12 participants (London cohort) was carried out using procedures 
designed to optimize the detection of mHTT. Samples were collected 
between 9:00 am and 10:00 am after fasting from midnight (water 
was permitted). After injection of up to 5 ml 2% lidocaine (Mercury 
Pharmaceuticals Inc.), 15–20 ml CSF was collected by lumbar punc-
ture using atraumatic needles (catalog 5181.27; Vygon) and placed 
immediately onto ice at the bedside. Collection vessels and plasticware 
throughout the processing chain were of polypropylene material to 
minimize protein adsorption (29). All processing was performed with-
out delay and on ice. CSF was centrifuged at 2,000 g for 10 minutes to 
remove cells, divided into aliquots, frozen immediately at –80°C, and 
analyzed within 4 months.
A second CSF sample set (Vancouver cohort), used for replication, 
was collected between 2004 and 2009. CSF was obtained from 40 par-
ticipants using similar methods (30), but sampling time and plasticware 
were not standardized, and samples were processed at room tempera-
ture. These samples were divided into aliquots and stored at –80°C.
Blood samples were obtained within 30 minutes of CSF sampling 
in sodium heparin cell preparation tubes in London (catalog 362753; 
BD) or EDTA tubes in Vancouver (catalog 367863; BD), and plasma was 
isolated by centrifugation according to the manufacturer’s instructions.
Antibodies. MW1 antibody specifically against the polyglutamine 
domain of HTT was developed by Paul Patterson (13). The anti-HTT 
antibody 2B7 recognizes the first 17 amino acids of the human HTT 
protein, and its generation and characterization were described pre-
viously (11). Labeling of the antibodies for application in the CSF 
detection assay was performed with Singulex Capture and Detection 
Labeling kits (catalogs 03-0077 and 03-0076; Singulex) according to 
the manufacturer’s instructions.
Recombinant purified HTT protein. Recombinant human pro-
teins containing the N-terminal sequence of HTT with 548 amino 
acids (N548) and polyglutamine repeats of different lengths were 
generated as previously described (31). In short, recombinant 
human GST-HTT proteins were expressed in E. coli BL-21 (catalog 
C2530H; New England BioLabs) and enriched using Glutathione 
Sepharose 4B Beads (catalog 17-0756-01; GE Healthcare). HTT 
proteins were then cleaved and further purified from the GST tags 
using PreScission Protease (catalog 27-0843-01; GE Healthcare). 
The HTT proteins were stored in PBS at pH 7.2 with 1% Tween-20 at 
–80°C until further use. Purity was assessed by Coomassie blue SDS 
page gel (catalogs 20278 and NW04120BOX; Life Technologies) 
(Supplemental Figure 1A).
SMC immunoassay for mutant HTT protein quantification in CSF 
and plasma. Dilution buffer (50 μl/well) containing 6% BSA, 0.8% 
Triton X-100, 750 mM NaCl, and complete protease inhibitor (cata-
log 04693116001; Roche); 15 μl per well artificial CSF (supplemented 
with 10% Tween-20 and complete protease inhibitor); and 135 μl/
well human sample (native CSF; plasma prediluted 1:3 in dilution 
buffer) were added to a 96-conical assay plate (catalog P-96-450V-C; 
Axygen). 2B7 antibody (100 μl/well) diluted to 1:400 with Erenna 
Assay Buffer (catalog 02-0474-00; Singulex) coupled with magnetic 
particles (catalog 03-0077-02; Singulex) at a ratio of 25 μg antibody 
per milligram magnetic particles was added, and the plate was sealed 
and incubated under shaking (600 rpm; Heidolph Titramax 1000 
Microplate Shaker) at room temperature for 1 hour. The plate was 
placed on a magnetic rack and washed 4 times with 200 μl 1× washing 
buffer (catalog 02-0111-00; Singulex). Washing buffer was removed, 
and 20 μl/well of 0.5 ng/μl diluted MW1 detection antibody labeled 
with detection fluorophore (catalog 03-0076-02; Singulex) at a ratio 
of 15.7 pmol fluorophore per micrgram MW1 was added to the plate. 
The plate was sealed and incubated under shaking (750 rpm) at room 
temperature for 1 hour. Plates were washed, and the antibody-antigen 
complex was transferred to a new 96-conical assay plate to eliminate 
nonspecific binding events to the plastic. After 4 washes with 200 μl 
1× washing buffer and aspiration, elution buffer (acidic glycine solu-
tion, 0.1 M, pH 2.7) was added to the plate, and the plate was incu-
bated under shaking (1,000 rpm) for 5 minutes. The eluted detection 
antibody was transferred to a Nunc 384-well analysis plate (catalog 
264573; Sigma-Aldrich) and neutralized with neutralization buffer 
(Tris, 1 M, pH 9). The analysis plate was spun down to eliminate foam-
ing and bubble formation, sealed, and subsequently analyzed with 
the Erenna Immunoassay System (Singulex).
All assays were performed by operators blinded to the clinical 
state of the participant.
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Quantification of other proteins. Hemoglobin quantification was 
performed with the Human Hemoglobin ELISA Kit (catalog E88-135; 
Bethyl Laboratories) according to the manufacturer’s instructions. Tau 
quantification was performed with the V-PLEX Plus Human Total Tau 
Kit (catalog K151LAE; Meso Scale Diagnostics) according to the man-
ufacturer’s instructions. Total protein quantification was performed 
with the Pierce BCA Protein Assay Kit (catalog 23225; Life Technol-
ogies) according to the manufacturer’s instructions. NFL was quanti-
fied using an ELISA kit (UmanDiagnostics) according to the manufac-
turer’s instructions. Femtomolar concentrations were estimated using 
canonical molar masses obtained from the UniProt database (32, 33).
Statistics. Analysis was performed with SAS, version 9.4 (SAS Inc.), 
StatXact, version 8, and R, version 3.1.1 (library boot). Statistical signif-
icance was defined by a P value of less than 0.05. Upper and lower lim-
its of quantification (ULoQ and LLoQ, respectively) were defined as 
the lowest and highest concentrations of the analyte in CSF that could 
be quantitatively determined with acceptable precision and accuracy. 
Suitability of data distribution for parametric statistical analysis was 
verified using Q-Q plots. Potentially confounding demographic vari-
ables (age, sex) were examined in preliminary analyses. Unless other-
wise noted, these were not significant confounders and were excluded 
from the final analyses. Differences between sites were examined 
using the 2-tailed Student’s t test with equal or unequal variances as 
determined by a P = 0.15 threshold on folded F tests. Detection of 
mHTT in mutation carriers versus controls was examined using Fis-
cher’s exact test. Differences in mHTT levels between groups of muta-
tion carriers were examined using weighted least-squares ANOVA 
(via PROC MIXED), with weighting based on different group-specific 
residual variances. Linear regression was used to examine the rela-
tionship between mHTT and disease burden, onset probability, NFL, 
tau, and clinical scores. There was non-normality in the distributions 
of plasma mHTT and CSF hemoglobin measurements. Group com-
parisons of these variables were therefore based on the Wilcoxon test. 
For plasma mHTT correlations, we report the Pearson’s correlation 
with BCA bootstrap CIs. For CSF hemoglobin, some measurements 
were outside the quantifiable range, and some others were detectable 
but outside the linear range. We therefore tested CSF hemoglobin cor-
relations using the Spearman’s rank test. Multiple comparisons were 
addressed via FDRs within conceptually related groups (34).
Study approval. All work involving human volunteers was per-
formed in accordance with the Declaration of Helsinki and approved 
by the Central London Research Ethics Committee and the University 
of British Columbia Clinical Research Ethics Board. All participants 
provided written informed consent.
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